• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Risk of infectious events in acute myocardial infarction patients treated with ticagrelor or clopidogrel.

作者信息

Lee Cheng-Han, Lin Hui-Wen, Lee Nan-Yao, Lin Sheng-Hsiang, Li Yi-Heng

机构信息

Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Biostatistics Consulting Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

出版信息

Eur J Intern Med. 2021 Mar;85:121-123. doi: 10.1016/j.ejim.2020.10.016. Epub 2020 Nov 14.

DOI:10.1016/j.ejim.2020.10.016
PMID:33199177
Abstract
摘要

相似文献

1
Risk of infectious events in acute myocardial infarction patients treated with ticagrelor or clopidogrel.替格瑞洛或氯吡格雷治疗的急性心肌梗死患者发生感染事件的风险。
Eur J Intern Med. 2021 Mar;85:121-123. doi: 10.1016/j.ejim.2020.10.016. Epub 2020 Nov 14.
2
Ticagrelor Versus Clopidogrel in Patients with Late or Very Late Stent Thrombosis.替格瑞洛与氯吡格雷治疗晚期或极晚期支架血栓形成患者的疗效比较。
Cardiovasc Drugs Ther. 2020 Oct;34(5):677-684. doi: 10.1007/s10557-020-07021-w. Epub 2020 Jun 22.
3
Use of Prasugrel and Ticagrelor in Stable Ischemic Heart Disease After Percutaneous Coronary Intervention, 2009-2016.2009 - 2016年普拉格雷和替格瑞洛在经皮冠状动脉介入治疗后稳定性缺血性心脏病中的应用
Circ Cardiovasc Interv. 2019 Jan;12(1):e007434. doi: 10.1161/CIRCINTERVENTIONS.118.007434.
4
Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention.替格瑞洛与氯吡格雷在经皮冠状动脉介入治疗中携带两个 CYP2C19 失活等位基因的患者中的比较。
Cardiovasc Drugs Ther. 2020 Apr;34(2):179-188. doi: 10.1007/s10557-020-06956-4.
5
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.氯吡格雷和强效 P2Y12 抑制剂对急性冠脉综合征或经皮冠状动脉介入治疗患者的死亡率和卒中的影响：系统评价和荟萃分析。
Thromb Haemost. 2013 Jan;109(1):93-101. doi: 10.1160/TH12-06-0377. Epub 2012 Nov 29.
6
Ticagrelor in Clopidogrel-Treated Patients With Chronic Coronary Syndrome Undergoing PCI: Translating Pharmacodynamic Into Clinical Evidence.替格瑞洛用于接受经皮冠状动脉介入治疗的氯吡格雷治疗的慢性冠状动脉综合征患者：将药效学转化为临床证据。
JACC Cardiovasc Interv. 2024 Jun 24;17(12):1422-1424. doi: 10.1016/j.jcin.2024.04.038. Epub 2024 Jun 5.
7
Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.替格瑞洛或普拉格雷与氯吡格雷三联抗血小板治疗联合糖蛋白 IIb/IIIa 抑制剂用于接受 PCI 的 STEMI 患者：一项荟萃分析。
BMC Cardiovasc Disord. 2020 Mar 12;20(1):130. doi: 10.1186/s12872-020-01403-6.
8
[The ISAR-REACT 5 trial: is there a winner between prasugrel and ticagrelor in acute coronary syndromes?].[ISAR-REACT 5试验：在急性冠状动脉综合征中，普拉格雷和替格瑞洛谁更胜一筹？]
G Ital Cardiol (Rome). 2020 Mar;21(3):171-174. doi: 10.1714/3306.32764.
9
Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor?急性冠状动脉综合征的当代抗血小板治疗：氯吡格雷和替格瑞洛在疗效及停药方面存在差异吗？
Intern Med J. 2017 Nov;47(11):1298-1305. doi: 10.1111/imj.13595.
10
Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice: Results From the Bern Percutaneous Coronary Intervention Registry.在常规临床实践中接受冠状动脉血运重建的患者中过早停用替格瑞洛的频率、原因和影响：来自伯尔尼经皮冠状动脉介入治疗注册研究的结果。
Circ Cardiovasc Interv. 2018 May;11(5):e006132. doi: 10.1161/CIRCINTERVENTIONS.117.006132.

引用本文的文献

1
Effects of Adding P2Y12 Inhibitor to Anti-staphylococcal Therapy on Bacterial Clearance in Patients With Staphylococcus aureus Bacteremia.在抗金黄色葡萄球菌治疗中添加P2Y12抑制剂对金黄色葡萄球菌菌血症患者细菌清除的影响。
Cureus. 2024 Oct 21;16(10):e71984. doi: 10.7759/cureus.71984. eCollection 2024 Oct.
2
affects myocardial function through TGF-β/Smad axis and pirfenidone.通过 TGF-β/Smad 轴和吡非尼酮影响心肌功能。
Biomol Biomed. 2024 Sep 6;24(5):1199-1215. doi: 10.17305/bb.2024.10246.
3
Protective Effect of Ticagrelor Against Infective Endocarditis Induced by Virulent in Mice.
替格瑞洛对小鼠强毒株诱导的感染性心内膜炎的保护作用。
JACC Basic Transl Sci. 2023 May 24;8(11):1439-1453. doi: 10.1016/j.jacbts.2023.02.003. eCollection 2023 Nov.
4
The Role of Platelets in Infective Endocarditis.血小板在感染性心内膜炎中的作用。
Int J Mol Sci. 2023 Apr 19;24(8):7540. doi: 10.3390/ijms24087540.
5
Non-Antimicrobial Adjuvant Therapy Using Ticagrelor Reduced Biofilm-Related Prosthetic Joint Infection.使用替格瑞洛的非抗菌辅助治疗可减少生物膜相关的人工关节感染。
Front Pharmacol. 2022 Jul 1;13:927783. doi: 10.3389/fphar.2022.927783. eCollection 2022.
6
Antiplatelet Therapy in Staphylococcus aureus Bacteremia: No Time Like the Past?金黄色葡萄球菌菌血症的抗血小板治疗：过去的时光并非一无是处？
Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0036522. doi: 10.1128/aac.00365-22. Epub 2022 May 10.
7
Antiplatelet therapy for Staphylococcus aureus bacteremia: Will it stick?金黄色葡萄球菌菌血症的抗血小板治疗：它会有效吗？
PLoS Pathog. 2022 Feb 10;18(2):e1010240. doi: 10.1371/journal.ppat.1010240. eCollection 2022 Feb.